The proceeds will be used for advancement of its core product pipelines.
Vivolight recently completed its Series D1 financing round worth over CNY 100 million.
The round was led by Huajin Capital and Fosun Health Capital, with participation from Kehe Capital and the existing investors Sequoia and Casstar. The proceeds will be used for the development and clinical trials of laser treatment products for craniocerebral, peripheral and ophthalmic fields.
Founded in 2012 and incubated by Xian Institute of Optics and Precision Mechanics, Chinese Academy of Sciences, Vivolight is a leading high-tech enterprise focusing on medical laser treatment in China. It is commited to the R&D of medical devices used for minimally invasive interventional diagnosis and treatment with the technology of laser, by leveraging the world-leading photoelectric technology and combining medicine and engineering.